Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Marijuana Smoking and Tracheobronchomalacia: Strong Recommendation Against

Understanding the Airway Vulnerability

  • Tracheobronchomalacia is characterized by structural weakness and flaccidity of the tracheal and bronchial walls due to loss of cartilaginous integrity, causing significant narrowing of the airway during forced expiration or coughing, with coronal narrowing exceeding 50% compared to less than 40% in healthy individuals 1, 2
  • The primary symptoms of tracheobronchomalacia are chronic cough and expiratory wheeze, which occur in almost all patients with this condition 1, 2

Why Marijuana Smoking is Particularly Harmful

  • Cough and wheeze, the hallmark symptoms of tracheobronchomalacia, would be directly worsened by marijuana smoking, which increases the likelihood of chronic cough and bronchial symptoms 1, 2

The Evidence on Cannabis and Respiratory Disease

  • The relationship between marijuana smoking and COPD development remains uncertain, with inconsistent findings regarding fixed airflow obstruction 3, 4, 5
  • The ASCO guidelines note that conflicting data exist regarding cannabis use and respiratory disease, with unclear associations with impaired lung function, asthma, and COPD 6, 7

Alternative Cannabis Delivery Methods

  • If a patient with tracheobronchomalacia has a compelling medical indication for cannabis use, oral administration is strongly preferred, as it avoids direct airway exposure while still delivering therapeutic cannabinoids, though it takes up to 2 hours for full effect 8, 9
  • The ASCO guidelines explicitly state that most cancer doctors prefer oral cannabis over inhalation 8, 9